Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed: 20,548
Companies: 1,769
Drugs tracked: 4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources

Quick answer

Matched placebo for test product, Duvakitug

Matched placebo for test product, Itepekimab

Matched placebo for test product, Itepekimab

Matched placebo for test product, Itepekimab

Nexviadyme 100 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion, avalglucosidase alfa, Nexviadyme 100 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion

PIMECROLIMUS , Amlitelimab, Matched placebo for test, Amlitelimab, -, TACROLIMUS

PIMECROLIMUS , Amlitelimab, Placebo, Amlitelimab, -, TACROLIMUS

PREVNAR 20 ®, Pneumococcal Conjugate Vaccine (PCV)

Placebo 15mg Tablets, Placebo 6mg tablets, venglustat GZ402671 - SAR402671, venglustat GZ402671 - SAR402671

Prograft 5 mg capsules, hard, Prograf 0,5 mg Hartkapseln, Prograf 1 mg Hartkapseln, Frexalimab, Prograft 0,5 mg capsules, hard, Prograft 1 mg capsules, hard, Prograf 5 mg Hartkapseln

Randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis

Randomized, open-label, Phase 3 study of SAR408701 versus docetaxel in previously treated, metastatic nonsquamous, non-small-cell lung cancer patients with CEACAM5-positive tumors

Rilzabrutinib

SAR439774, SAR439774

Sar444671 placebo - matched placebo for test, Rilzabrutinib

Sar444671 placebo - matched placebo for test, Rilzabrutinib

Teplizumab, Matched placebo for test product

Vaxneuvance suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed), Pneumococcal Conjugate Vaccine (PCV)

matched placebo for test product, Duvakitug

riliprubart

riliprubart placebo, solution for injection in prefilled pen (PFP), riliprubart placebo, solution for injection in vial, riliprubart, riliprubart

riliprubart, -, riliprubart placebo solution for injection in prefilled pen, placebo matching IVIg, riliprubart, riliprubart placebo solution for injection in vial, -

Frequently asked questions